In the final set of experiments, we focused on comparing the anti-tumor activity and expansion/persistence of EM- and CM-enriched CAR T cell products in vivo using a subcutaneous (s.c.)HER2+ JIMT-1 xenograft model, in which either tumor cells or CAR T cells were genetically modified to express firefly luciferase (ffLuc). This evidence concerns the gene ERBB2 and neoplasm.